A Trial Assessing Chemo Mouthpiece Device With Best Supportive Care for Symptoms of Chemotherapy-Induced Oral Mucositis

Completed · Not applicable

Conditions studied: Oral Mucositis

In brief

This study will compare the use of the Chemo MouthpieceTM device along with best supportive oral care to best supportive oral care alone to rate the effectiveness of Chemo MouthpieceTM in lessening symptoms associated with chemotherapy regimen known to place patients at risk for symptomatic mucositis and, of those, chemotherapy regimens for which ice-based cryotherapy has been demonstrated to have a favorable impact on oral mucositis symptom management. Subjects who are receiving standard chemotherapy regimens will be randomly assigned to receive either study device and oral care ingredients or oral care ingredients only. All subjects will complete daily diaries for the first 14 days of chemotherapy Cycles 1 and 2. Subjects who are assigned to the study device arm will use the device during their chemotherapy infusion in clinic and will continue to use the device at home ,at least twice daily, for the first six (6) days of chemotherapy Cycles 1 and 2. Prior to the first chemotherapy infusion in Cycle 3, all subjects in the study regardless of treatment assignment will have the option of using the Chemo MouthpieceTM for subsequent cycles.

Key facts

Study ID

NCT04595838

Run by

Chemo Mouthpiece

People needed

176

Starts

2020-08-31

Expected to finish

2023-05-18

Last updated by the study team

2023-09-18

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged 18-80 years
• Planned to receive at least 2 cycles of infused stomatotoxic chemotherapy regimens such as:
• CMF (cyclophosphamide (Cytoxan), methotrexate, 5-FU)
• Standard AC+T regimen (doxorubicin (Adriamycin), cyclophosphamide (Cytoxan), Taxane [paclitaxel (Taxol) or docetaxel (Taxotere)]) or any combination of two or more components (e.g., ACT, TAC, TA, AT, AC)
• ABVD (doxorubicin (Adriamycin), bleomycin, vinblastine, dacarbazine)
• FOLFIRI (irinotecan, 5-FU, leucovorin)
• Any other 5-FU-based regimen (excluding FOLFOX)
• Be willing and able to complete all study-related activities
• Properly obtained written informed consent

You may not qualify if…

• Receiving any oxaliplatin-containing chemotherapy regimen, such as FOLFOX
• Concurrent radiotherapy
• Unable or unwilling to complete study assessments
• Unable or unwilling to avoid using ice chips
• Known allergy to silicone
• Concurrent participation in another interventional clinical study or use of another investigational agent within 30 days prior to randomization
• Any other clinical or psychiatric condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study or unable to comply with the protocol
• Chronic use of opioid analgesics

Where it is running

• Chan Soon-Shiong Institute for Medicine — Costa Mesa, California, United States
• Goshen Health — Goshen, Indiana, United States
• Revive Research Institute — Farmington Hills, Michigan, United States
• Revive Research Institute, Inc. — Sterling Heights, Michigan, United States
• Phelps Health — Rolla, Missouri, United States
• Inspira Medical Center — Mullica Hill, New Jersey, United States
• Inspira Medical Center — Vineland, New Jersey, United States
• Erie County Medical Center — Buffalo, New York, United States
• New York Cancer & Blood Specialists — New York, New York, United States
• The Christ Hospital — Cincinnati, Ohio, United States
• Gibbs Cancer Center — Spartanburg, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.